Jorge Blando
AstraZeneca (Netherlands)(NL)AstraZeneca (Japan)(JP)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Cancer, Lipids, and Metabolism, Immunotherapy and Immune Responses, Immune cells in cancer, Renal cell carcinoma treatment
Most-Cited Works
- → B cells and tertiary lymphoid structures promote immunotherapy response(2020)2,549 cited
- → Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade(2016)1,002 cited
- → Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma(2018)810 cited
- → Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis(2018)703 cited
- → VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer(2017)587 cited
- → Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study(2018)563 cited
- → Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study(2017)384 cited
- → Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma(2019)371 cited
- → Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers(2018)371 cited
- → The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia(2018)337 cited